Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the ...

Digital Customer Success Benchmark reveals a striking AI implementation crisis: while 72% of CS teams call AI "critical" by 2026, only 32% run even a single live use case, with just 3% achieving ...

SOUTH SAN FRANCISCO, Calif. & SEATTLE, May 13, 2025--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg ...

Over two thirds of patients with hidradenitis suppurativa experience fewer flares, new lesions, and improved quality of life while using GLP-1 receptor agonists.

Mirum Pharmaceuticals, Inc. today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., ...

Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases.

Two authors declared receiving personal fees from Abbvie, Medscape, Novartis, UCB, and Sonoma Biotherapeutics, Aurinia, UCB, and AstraZeneca and serving as vice president of the Hidradenitis ...

and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown ...

and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown ...

Sheehy joins from Sonoma Biotherapeutics, where he served as chief legal officer and secretary. He has led global legal and compliance operations for biopharmaceutical companies for nearly two decades ...